Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (October 2006)
13 slides from Cogstate's shareholder meeting presentation, Oct 26, 2006
Slide 1: Annual General Meeting 26 October 2006
CogState 9B, Annual General Meeting 26 October 2006
Slide 2: Martyn Myer, Chairman
oe .rrtrt~—<—s——C:«=C i<‘(<a<Ssizis.CCis¥S‘ Martyn Myer Chairman
Slide 3: A year of progress
oe .rrtrt~—<—s——C:«=C i<‘(<a<Ssizis.CCis¥S‘ A year of progress Simplified business model Revenue growth of 102% Focus of development and commercialisation of computer based tests of cognition Strategic decision to focus on sales into the Clinical trials market Divestment of therapeutic portfolio Maj
Slide 4: Achievements throughout the year
oe .rrtrt~—<—s——C:«=C i<‘(<a<Ssizis.CCis¥S‘ Achievements throughout the year * Secured $1.3m product development funding from Pfizer ¢ Placement raised $300k in December * 1:7 Rights Issue raised $550k in February ¢ Appointed former Pfizer scientist, Prof. Peter Snyder as a consultant in the USA ¢ A
Slide 5: Brad O'Connor, Chief Executive Officer
oe .rrtrt~—<—s——C:«=C i<‘(<a<Ssizis.CCis¥S‘ Brad O’Connor Chief Executive Officer
Slide 6: Financial Result: June 2006
| Eee Financial Result : 30 June 2006 * Sales revenue $2.08m (2005: $1.03m) representing growth of 102% ¢ EBIT loss of $1.95m (2005: $2.85m) ¢ H1 EBIT loss $1.60m : H2 EBIT loss $0.35m ¢ Restructure reduced operating costs by more than $0.80m for H2
Slide 7: Revenue growth by quarter
oe .rrtrt~—<—s——C:«=C i<‘(<a<Ssizis.CCis¥S‘ Revenue growth by quarter CogState sales revenue, by quarter
Slide 8: Quarterly cash flows since 1 July 2005
te... hl lUtCi«COUC«s«CCOCNCNOCOCNCOCCN#CN(OiéiéCO Quarterly cash flows since 1 July 2005 Cash Receipts 06 Apr-Jun 2006 Jul-Sep _ | Eid Staff Costs ‘006 Jan-Mar $000 2005 Jul-Sep 2005 Oct-Dec —e— Cash Flow
Slide 9: Key players in the CNS market
of... lUmUlrrCCSCWCsCUCC:CCC.C.C..LUt.. Key players in the CNS market Key Players in the Global CNS market, by Sales, 2004 Johnson & Johnson 12% Aim to build a . relationships with world-class partners GiaxoSmithitine Specifically target “ 4-5 big pharmaceutical companies with Foret, Wyeth Sanof ven
Slide 10: Strategy for revenue growth
oe .rrtrt~—<—s——C:«=C i<‘(<a<Ssizis.CCis¥S‘ Strategy for revenue growth ¢ Continued use of technology by Pfizer ¢ Agreements signed with GlaxoSmithKline, Merck & Lundbeck ¢ Establishment of US office ¢ Continue to focus on large pharmaceutical companies with pipeline of CNS drugs ¢ Ensure we have th
Slide 11: Continued investment in R&D
oe .rrtrt~—<—s——C:«=C i<‘(<a<Ssizis.CCis¥S‘ Continued investment in R&D * Secured $1.3m of product development funding from Pfizer ¢ Working in conjunction with Pfizer & Yale to develop pediatric tests * Development of dedicated batteries of tests for Schizophrenia, ADHD and MCI ¢« Launch of DataPoi
Slide 12: Outlook
| Eee Outlook ¢ Expansion of sales and marketing operations in the US, including new staff ¢ Continue to foster close relationships with “big pharma” companies * Continue excellent revenue growth ¢ Expanded product offering 12
Slide 13: Brad O'Connor, Chief Executive Officer
a Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 boconnor@cogstate.com 13